The SunTrust Banks Equities Analysts Lower Earnings Estimates for Eli Lilly and Co. (LLY)

The SunTrust Banks Equities Analysts Lower Earnings Estimates for Eli Lilly and Co. (LLY)

Eli Lilly and Co. (NYSE:LLY) – Stock analysts at SunTrust Banks lowered their Q4 2016 earnings per share (EPS) estimates for Eli Lilly and in a research note issued to investors on Wednesday. SunTrust Banks analyst J. Boris now anticipates that the firm will post earnings per share of $0.94 for the quarter, down from their prior estimate of $1.03. SunTrust Banks also issued estimates for Eli Lilly and’s FY2018 earnings at $4.45 EPS and FY2020 earnings at $6.19 EPS.

A number of other equities analysts have also issued reports on LLY. Leerink Swann reiterated an “outperform” rating and issued a $105.00 target price on shares of Eli Lilly and in a research report on Saturday, August 13th. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $88.00 target price for the company in a research report on Thursday, October 20th. JPMorgan Chase & Co. set a $85.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Thursday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $94.00 target price on shares of Eli Lilly and in a research report on Tuesday, September 27th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $108.34.

Eli Lilly and (NYSE:LLY) opened at 69.12 on Monday. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $88.16. The firm has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. The stock has a 50 day moving average of $76.69 and a 200-day moving average of $77.92.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.89 EPS.

A number of hedge funds have recently bought and sold shares of the stock. RWC Asset Management LLP raised its stake in Eli Lilly and by 3.7% in the third quarter. RWC Asset Management LLP now owns 712,392 shares of the company’s stock worth $57,177,000 after buying an additional 25,429 shares in the last quarter. ETRADE Capital Management LLC raised its stake in Eli Lilly and by 37.7% in the third quarter. ETRADE Capital Management LLC now owns 12,904 shares of the company’s stock worth $1,036,000 after buying an additional 3,531 shares during the period. D.A. Davidson & CO. raised its stake in Eli Lilly and by 53.1% in the third quarter. D.A. Davidson & CO. now owns 41,009 shares of the company’s stock worth $3,289,000 after buying an additional 14,215 shares during the period. Sheets Smith Wealth Management raised its stake in Eli Lilly and by 28.8% in the third quarter. Sheets Smith Wealth Management now owns 3,801 shares of the company’s stock worth $305,000 after buying an additional 851 shares during the period. Finally, Piedmont Investment Advisors LLC bought a new stake in Eli Lilly and during the third quarter worth about $17,345,000. 75.11% of the stock is owned by institutional investors.

In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.20% of the company’s stock.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s dividend payout ratio is presently 88.70%.

Eli Lilly and Company Profile

Related posts

Leave a Comment